Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-34576900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Silence Therapeutics (LON:SLN) Frequently Asked Questions
What is Silence Therapeutics' stock symbol?
Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."
How were Silence Therapeutics' earnings last quarter?
Silence Therapeutics plc (LON:SLN) announced its quarterly earnings results on Tuesday, September, 11th. The company reported ($12.40) earnings per share (EPS) for the quarter. View Silence Therapeutics' Earnings History.
What is the consensus analysts' recommendation for Silence Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silence Therapeutics.
Has Silence Therapeutics been receiving favorable news coverage?
Headlines about SLN stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Silence Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Silence Therapeutics.
Who are some of Silence Therapeutics' key competitors?
Some companies that are related to Silence Therapeutics include Kodiak Sciences (KOD), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Biotest (BIO), Neptune Wellness Solutions (NEPT), Starpharma (SPL), Oxford BioMedica (OXB), TELIX Pharmaceutical (TLX), Aprea Therapeutics (APRE), Bellus Health (BLU), Theratechnologies (TH), ProMetic Life Sciences (PLI), Resverlogix (RVX), CEL-SCI (CVM) and Pfenex (PFNX).
What other stocks do shareholders of Silence Therapeutics own?
Who are Silence Therapeutics' key executives?
Silence Therapeutics' management team includes the folowing people:
- Dr. David Horn Solomon, CEO & Director (Age 59)
- Dr. Rob Quinn, Chief Financial Officer
- Dr. Mark Cameron, Head of Chemistry
- Mr. Richard Jenkins, Head of Clinical Devel.
How do I buy shares of Silence Therapeutics?
Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Silence Therapeutics' stock price today?
One share of SLN stock can currently be purchased for approximately GBX 256.
How big of a company is Silence Therapeutics?
What is Silence Therapeutics' official website?
How can I contact Silence Therapeutics?
Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.
MarketBeat Community Rating for Silence Therapeutics (LON SLN)
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
